These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27405679)

  • 21. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
    Van Damme A; Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy: Genie in a vector.
    Gould J
    Nature; 2014 Nov; 515(7528):S160-1. PubMed ID: 25427205
    [No Abstract]   [Full Text] [Related]  

  • 24. AAV-mediated gene therapy for hemophilia.
    Couto LB; Pierce GF
    Curr Opin Mol Ther; 2003 Oct; 5(5):517-23. PubMed ID: 14601521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy.
    Gnatenko DV; Saenko EL; Jesty J; Cao LX; Hearing P; Bahou WF
    Br J Haematol; 1999 Jan; 104(1):27-36. PubMed ID: 10027708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
    Youjin S; Jun Y
    Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy - are we ready now?
    Kaczmarek R
    Haemophilia; 2022 May; 28 Suppl 4(Suppl 4):35-43. PubMed ID: 35521736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical and clinical gene therapy for haemophilia.
    Chuah MK; Collen D; Vandendriessche T
    Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemophilia gene therapy-New country initiatives.
    Reiss UM; Zhang L; Ohmori T
    Haemophilia; 2021 Feb; 27 Suppl 3():132-141. PubMed ID: 32638467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia?
    Liras A
    Thromb Res; 2011 Jul; 128(1):8-13. PubMed ID: 21396685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy for haemophilia: the end of a 'royal pathology' in the third millennium?
    Liras A
    Haemophilia; 2001 Sep; 7(5):441-5. PubMed ID: 11554929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AAV-mediated gene transfer for treatment of hemophilia.
    Wang L; Herzog RW
    Curr Gene Ther; 2005 Jun; 5(3):349-60. PubMed ID: 15975012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
    Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
    Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
    Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
    Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.